Long-Term Assets: The sum of all assets classified as non-current.
Allergy Therapeutics (AGYTF) had Long-Term Assets of $67.34M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$44.88M |
|
$56.20M |
|
|
Long-Term Assets |
$67.34M |
$87.41M |
|
$35.19M |
|
$75.33M |
|
$88.70M |
|
$123.89M |
|
$-36.50M |
|
$-41.99M |
|
$-36.48M |
|
-- |
|
| Cash Flow Statement Financials | |
$-36.38M |
|
$-3.73M |
|
$40.33M |
|
$16.71M |
|
$16.55M |
|
$-0.16M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|